Get started
THERANEXUSTHERANEXUSTHERANEXUS

THERANEXUS

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals

ALTHX fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. It offers psychotropic drugs for the treatment of neurological disorders such as narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain, psychiatric conditions, and epilepsy. The company was founded by Franck Joseph Louis Mouthon and Mathieu Bernard Mari Charveriat on March 19, 2013 and is headquartered in Lyon, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ALTHX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company